Market Place
Sourcing Support
FDA Grants Fast Track To Phanes’ PT217 For NEPC
04 Dec 2024 //
PR NEWSWIRE
Veravas with Phanes Biotech on Tau Pathology Test for Alzheimer`s
07 Nov 2024 //
BUSINESSWIRE
Phanes Therapeutics Doses First Patient In PT886 Combo Therapy Study
09 Sep 2024 //
PR NEWSWIRE
Phanes Receives FDA Orphan Drug Designation For Neuroendocrine Carcinoma
16 Aug 2024 //
PR NEWSWIRE
Phanes Therapeutics, Inc.: Clinical Supply Agreement with Roche for PT217
08 May 2024 //
PR NEWSWIRE
Phanes Therapeutics` PT217 granted Fast Track Designation by the FDA
08 Apr 2024 //
PR NEWSWIRE
Phanes Therapeutics` PT886 granted Fast Track designation by the FDA
20 Mar 2024 //
PR NEWSWIRE
Phanes announces granting of trademarks for proprietary technology platforms
29 Jan 2024 //
PR NEWSWIRE
Phanes Therapeutics, Inc. Announces Clinical Trial Collaboration with Merck
16 Oct 2023 //
PR NEWSWIRE
Phanes Therapeutics Appoints Prof. Shun Lu to its Clinical Advisory Board
14 Sep 2023 //
PR NEWSWIRE
Phanes Therapeutics Announces First Patient Dosed in Phase 1 Study of PT217
07 Sep 2023 //
PR NEWSWIRE
Phanes Announces the Establishment of Oncology Clinical Advisory Board
05 Sep 2023 //
PR NEWSWIRE
Phanes Therapeutics announces the appointment of Rita Laeufle, MD, PhD, asCMO
30 May 2023 //
PR NEWSWIRE
Phanes Therapeutics Announces First Patient Dosed in Phase 1 Study of PT886
20 Mar 2023 //
PR NEWSWIRE
Phanes Therapeutics entered into collaboration with Xyphos
06 Mar 2023 //
PR NEWSWIRE
Phanes Therapeutics` anti-claudin 18.2 antibody patent granted in the US
17 Jan 2023 //
PR NEWSWIRE
Phanes Therapeutics Announces Supply Agreement with BeiGene to Evaluate PT199
08 Dec 2022 //
PRNEWSWIRE
Phanes announces FDA IND clearance for PT217, an anti-DLL3/anti-CD47 antibody
14 Oct 2022 //
PRNEWSWIRE
Phanes Therapeutics begins patient dosing in phase 1 study of PT199
24 Aug 2022 //
PHARMABIZ
Phanes Therapeutics` anti-CD47 antibody patent granted in the US
02 Aug 2022 //
PRNEWSWIRE
Phanes` PT886 granted ODD for pancreatic cancer by the FDA
30 Jun 2022 //
PRNEWSWIRE
Phanes Therapeutics` PT217 receives ODD for SCLC from the FDA
21 Jun 2022 //
PRNEWSWIRE
Phanes Therapeutics announces FDA IND clearance for PT886 in cancers
15 Jun 2022 //
PRNEWSWIRE
Phanes revealed manufacturing validation of PACbody and SPECpair at AACR
20 Apr 2022 //
PRNEWSWIRE
Phanes Therapeutics` anti-CD73 antibody patent granted in the US
12 Apr 2022 //
PRNEWSWIRE
Phanes Tx announces FDA IND clearance for PT199
22 Mar 2022 //
PRNEWSWIRE
Phanes Therapeutics` antibody patent granted
04 Feb 2022 //
PRNEWSWIRE
Phanes Tx announces the appointment of Vice President of Business Development
11 Jan 2022 //
PRNEWSWIRE
Phanes reveals SPECpair™ technology platform that enhances manufacturability
10 Sep 2021 //
BIOSPACE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.